Gen-Probe acquires Prodesse

NewsGuard 100/100 Score
Oct 23 2009

Gen-Probe (Nasdaq: GPRO) announced today that the Company has completed its acquisition of Prodesse, Inc., a leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash.

Gen-Probe's purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.

"We are delighted to complete this acquisition ahead of schedule and welcome Prodesse's employees to Gen-Probe," said Carl Hull, Gen-Probe's president and chief operating officer. "Prodesse has had great success introducing clinically differentiated assays for infectious diseases, including influenza, and we believe our global commercial infrastructure will both facilitate and accelerate their next stage of growth."

Source:

Gen-Probe Incorporated

Posted in:

Tags: , , , , ,

Comments (0)

Suggested Reading

Study finds higher burden of neurologic disease after influenza than COVID-19 hospitalization
New study offers promising targets for universal influenza B vaccine
Researchers study newborn piglets to better understand the progression of influenza
H5N1 variant spreads between species, endangering wildlife
New study finds 4’-fluorouridine effective against avian influenza in vitro and in vivo
Two proteins in the blood could predict dengue severity
New 4-in-1 test can differentiate between swine flu, COVID-19, RSV, and influenza
Avian influenza A H5N1 virus impacts wide range of wildlife in the U.S., study shows

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Newly identified antibodies target a hard-to-spot region of the influenza virus